Cumulative life course impairment (CLCI) is the irreversible harm resulting from the chronic burden of disease, such as psoriasis. This cumulative impact encompasses physical, psychological, social, and emotional challenges that can significantly alter the life trajectory of a patient with psoriasis. The risk of CLCI and the impact of living with psoriasis are exacerbated when the disease is inadequately managed. Even with improvements in skin symptoms, psychological factors, such as anxiety about relapse, can persist, adding to the long-term burden. The development and validation of screening tools to better identify and assess CLCI may provide a valuable framework for clinical practice, supporting holistic care and serving as an effective measure for evaluating the long-term impact of new therapies.
LevyARDavieAMBrazierNC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432-1440. doi:10.1111/J.1365-4632.2011.05359.X
3.
WarrenRBKleynCEGulliverWP.Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol. 2011;164(S1):1-14. doi:10.1111/J.1365-2133.2011.10280.X
4.
WisemanMCO’TooleA.Understanding cumulative life course impairment in psoriasis: impact on patient management. Can Dermatol Today. 2021;2(S6):2-15.
5.
CampanatiAMaraniAMartinaEDiotalleviFRadiGOffidaniA.Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches. Biomedicines. 2021;9(11):1511. doi:10.3390/BIOMEDICINES9111511
6.
IwakuraY.The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116(5):1218-1222. doi:10.1172/JCI28508
7.
LuanY-YYaoY-M.The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol. 2018;9:1302. doi:10.3389/fimmu.2018.01302
8.
KormanNJ.Management of psoriasis as a systemic disease: what is the evidence?Br J Dermatol. 2020;182(4):840-848. doi:10.1111/bjd.18245
9.
DaugaardCIversenLHjulerKF.Comorbidity in adult psoriasis: considerations for the clinician. Psoriasis. 2022;12:139. doi:10.2147/PTT.S328572
10.
von StülpnagelCCAugustinMDüpmannLda SilvaNSommerR.Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases—a systematic review. J Eur Acad Dermatol Venereol. 2021;35(11):2166-2184. doi:10.1111/jdv.17348
11.
GarshickMKKimballAB.Psoriasis and the life cycle of persistent life effects. Dermatol Clin. 2015;33(1):25-39. doi:10.1016/J.DET.2014.09.003
12.
KuhDBen-ShlomoYLynchJHallqvistJPowerC.Life course epidemiology. J Epidemiol Community Health. 2003;57(10):778-783. doi:10.1136/JECH.57.10.778
13.
LinderMDPiasericoSAugustinM, et al. Psoriasis—the life course approach. Acta Derm Venereol. 2016;96(217):102-108. doi:10.2340/00015555-2430
14.
KimballABGielerULinderDSampognaFWarrenRAugustinM.Psoriasis: is the impairment to a patient’s life cumulative?J Eur Acad Dermatol Venereol. 2010;24(9):989-1004. doi:10.1111/J.1468-3083.2010.03705.X
15.
ArmstrongAJarvisSBoehnckeW-H, et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32(12):2200-2207. doi:10.1111/jdv.15065
16.
GinsburgIHLinkBG.Psychosocial consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol. 1993;32(8):587-591. doi:10.1111/j.1365-4362.1993.tb05031.x
17.
RomitiRMagalhãesRFDuarteGV.Cumulative life course impairment in patients with dermatological diseases, with a focus on psoriasis. An Bras Dermatol. 2024;99(2):269-276. doi:10.1016/J.ABD.2023.08.006
18.
ArmstrongAWHarskampCTDhillonJSArmstrongEJ.Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170(2):304-314. doi:10.1111/bjd.12670
19.
SmithBBrownEKimYJAfolabiATungJK.Association between psoriasis and electronic cigarette usage among adults in the United States. J Am Acad Dermatol. 2025;93(1):217-219. doi:10.1016/j.jaad.2025.03.060
20.
BrenautEHorreauCPouplardC, et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(S3):30-35. doi:10.1111/jdv.12164
21.
KaoLTLiIHWangWMLeeHCKaoHHPanKT.Illicit drugs, cannabis, and psoriasis in the United States: National Health and Nutrition Examination Survey. J Am Acad Dermatol. 2020;82(6):1514-1517. doi:10.1016/j.jaad.2020.01.001
22.
WeissSCKimballABLiewehrDJBlauveltATurnerMLEmanuelEJ.Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47(4):512-518. doi:10.1067/mjd.2002.122755
23.
GuptaMASchorkNJGuptaAKKirkbySEllisCN.Suicidal ideation in psoriasis. Int J Dermatol. 1993;32(3):188-190. doi:10.1111/j.1365-4362.1993.tb02790.x
24.
BhattiZUSalekSSBoltonCE, et al. The development and validation of the Major Life Changing Decision Profile (MLCDP). Health Qual Life Outcomes. 2013;11(1):78. doi:10.1186/1477-7525-11-78
25.
PariserDSchenkelBCarterCFarahiKBrownTMEllisCN.A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatolog Treat. 2016;27(1):19-26. doi:10.3109/09546634.2015.1044492
26.
FinlayAYColesEC.The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132(2):236-244. doi:10.1111/J.1365-2133.1995.TB05019.X
27.
RosSPuigLCarrascosaJM.Cumulative life course impairment: the imprint of psoriasis on the patient’s life. Actas Dermosifiliogr. 2014;105(2):128-134. doi:10.1016/j.ad.2013.02.009
28.
MarzanoAVGenoveseGCasazzaG, et al. Evidence for a “window of opportunity” in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133-140. doi:10.1111/bjd.18983
29.
HornEJFoxKMPatelVChiouCFDannFLebwohlM.Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57(6):957-962. doi:10.1016/J.JAAD.2007.06.042
30.
MahilSKEzejimoforMCExtonLS, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020;183(4):638-649. doi:10.1111/bjd.19325
31.
SchäkelKReichKAsadullahK, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (“clinical super response”): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016-2027. doi:10.1111/JDV.19236
32.
SvedbomAMallbrisLLarssonP, et al. Long-term outcomes and prognosis in new-onset psoriasis. JAMA Dermatol. 2021;157(6):684-690. doi:10.1001/JAMADERMATOL.2021.0734
33.
PappKALebwohlMGPuigL, et al. Long-term safety and efficacy of risankizumab to treat moderate-to-severe plaque psoriasis: final LIMMitless phase 3, open-label extension trial results. Am J Clin Dermatol. 2025;26(5):829-841. doi:10.1007/s40257-025-00964-6
34.
WarrenRBLebwohlMThaçiD, et al. Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. Br J Dermatol. 2025;193(1):44-55. doi:10.1093/bjd/ljaf032
35.
RiazSEmamSWangTGniadeckiR.Negative impact of comorbidities on all-cause mortality of patients with psoriasis is partially alleviated by biologic treatment: a real-world case-control study. J Am Acad Dermatol. 2024;91(1):43-50. doi:10.1016/j.jaad.2024.01.078
36.
LangleyRGPoulinYSrivastavaB, et al. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case-control analysis. J Am Acad Dermatol. 2021;84(1):60-69. doi:10.1016/j.jaad.2020.08.032
37.
ChoiHUcedaDEDeyAK, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective, observational study. Circ Cardiovasc Imaging. 2020;13(9):e011199. doi:10.1161/CIRCIMAGING.120.011199
38.
AlinaghiFCalovMKristensenLE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19. doi:10.1016/j.jaad.2018.06.027
39.
GisondiPBellinatoFTargherGIdolazziLGirolomoniG.Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68-73. doi:10.1136/annrheumdis-2021-219961
40.
Acosta FelquerMLLoGiudiceLGalimbertiMLRosaJMazzuoccoloLSorianoER.Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74-79. doi:10.1136/annrheumdis-2021-220865
41.
SinglaSPutmanMLiewJGordonK.Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200-e207. doi:10.1016/S2665-9913(23)00034-6
42.
MatteiPLCoreyKCKimballAB.Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333-337. doi:10.1111/jdv.12106
43.
PuigLThomHMollonPTianHRamakrishnaGS.Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213-220. doi:10.1111/jdv.14007
44.
BasraMKASalekMSCamilleriLSturkeyRFinlayAY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27-33. doi:10.1159/000365390
45.
DuarteGVde OliveiraMFSPFolladorISilvaTSFilhoEMC. Diagnosis and underdiagnosis of comorbidities in psoriasis patients—need for a multidisciplinary approach. An Bras Dermatol. 2016;91(6):743-747. doi:10.1590/ABD1806-4841.20164716
46.
GladmanDDPoulinYAdamsK, et al. Treating psoriasis and psoriatic arthritis: position paper on applying the treat-to-target concept to Canadian daily practice. J Rheumatol. 2017;44(4):519-534. doi:10.3899/JRHEUM.161473
47.
GuptaMAGuptaAK.Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003;4(12):833-842. doi:10.2165/00128071-200304120-00003
48.
FlemingPRoubilleCRicherV, et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015;29(6):1063-1070. doi:10.1111/JDV.12909
49.
SalameNEhsani-ChimehNArmstrongAW.Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study. J Dermatolog Treat. 2019;30(2):135-140. doi:10.1080/09546634.2018.1476654
AugustinM.Cumulative life course impairment: identifying patients at risk. Curr Probl Dermatol. 2013;44:74-81. doi:10.1159/000350555
54.
StroberBEvan der WaltJMArmstrongAW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther. 2019;9(1):5-18. doi:10.1007/S13555-018-0279-5
55.
PattinsonRTrialonis-SuthakharanNPicklesT, et al. Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure. Br J Dermatol. 2024;191(6):936-948. doi:10.1093/bjd/ljae267
56.
Braren-von StülpnagelCCAugustinMWestphalLSommerR.Development of measurement tools to assess cumulative life course impairment in patients with chronic skin diseases. J Eur Acad Dermatol Venereol. 2023;37(8):1626-1633. doi:10.1111/JDV.18977
